WHAT IS CLAIMED IS:

1. A pharmaceutical composition comprising (i) a norepinephrine reuptake inhibitor (NRI), (ii) pimavanserin, and (iii) a pharmaceutically acceptable carrier.

2. The composition of claim 1, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

3. The composition of claim 2, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

4. The composition of claim 1, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Phenmetrazine, Protryptyline, Radafaxine, Tapentadol (Nucynta), Teniloxazine (Lucelan, Metatone) and Venlafaxine.

5. The composition of claim 1, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

6. The composition of claim 5, wherein the NRI is Atomoxetine.

7. The composition of claim 6, wherein the dosage of Atomoxetine is 20 – 100 mg.

8. The composition of any one of claims 1-7, wherein the single composition is an oral administration form.

9. The composition of claim 8, wherein the oral administration form is a pill, tablet, troche, or capsule.

10. The composition of any one of claims 1-9, for use in therapy.

11. A kit comprising a norepinephrine reuptake inhibitor (NRI) and pimavanserin.

12. Use of an effective amount of (i) a norepinephrine reuptake inhibitor (NRI) and (ii) pimavanserin in the preparation of a medicament for the treatment of a disease or disorder associated with pharyngeal airway collapse in a subject while the subject is in a non-fully conscious state, wherein the medicament is to be administered to a subject in need thereof.

13. The use of claim 12, wherein the NRI is a norepinephrine selective reuptake inhibitor (NSRI).

14. The use of claim 13, wherein the NSRI is selected from the group consisting of Amedalin, Atomoxetine, CP-39,332, Daledalin, Edivoxetine, Esreboxetine, Lortalamine, Nisoxetine, Reboxetine, Talopram, Talsupram, Tandamine, and Viloxazine.

15. The use of claim 12, wherein the NRI is a norepinephrine non-selective reuptake inhibitor (NNRI) selected from the group consisting of Amitriptiline, Amoxapine, Bupropion, Ciclazindol, Desipramine, Desvenlafaxine, Dexmethilphenidate, Diethylpropion, Doxepin, Duloxetine, Imipramine, Levomilnacipran, Manifaxine, Maprotiline, Methylphenidate, Milnacipran, Nefazodone, Nortriptyline, Phendimetrazine, Phenmetrazine, Protryptyline, Radafaxine, Tapentadol, Teniloxazine, and Venlafaxine.

16. The use of claim 12, wherein the NRI is selected from the group consisting of Atomoxetine and Reboxetine.

17. The use of claim 16, wherein the NRI is Atomoxetine.

18. The use of claim 17, wherein the Atomoxetine is to be administered at a dose of 20 – 100 mg.

19. The use of claim 18, wherein the Atomoxetine is to be administered at a dose of 25 – 75 mg.

20. The use of claim 12, wherein the pimavanserin is to be administered at a dose of 20-40 mg, preferably 34 mg.

21. The use of any one of claims 12-20, wherein the disease or disorder is Obstructive Sleep Apnea or Simple Snoring.

22. The use of claim 21, wherein the disease or disorder is Obstructive Sleep Apnea.

23. The use of claim 12, wherein the non-fully conscious state is sleep.

24. The use of claim 12, wherein the NRI and the pimavanserin are to be administered in a single composition.

25. The use of claim 24, wherein the single composition is an oral administration form.

26. The use of claim 25, wherein the oral administration form is a syrup, pill, tablet, troche, or capsule.